Elicio Therapeutics Q3 2024 net loss $18.8M, cash $26M; AMPLIFY-7P enrollment on track

Elicio Therapeutics, Inc.

2024-Q3 EPS reported -$3.23

Net loss $18.8M ($1.39 per share) vs $10.7M ($1.27) YoY; includes $8.5M non-cash warrant liability change.
Cash and cash equivalents $26.0M as of Sept 30, 2024; operational changes expected to fund into Q2 2025.
AMPLIFY-7P Phase 2 randomized study enrollment completion expected Q4 2024; interim DFS analysis H1 2025.
SITC poster showed durable T cell responses and antigen spreading in KRAS mutant tumors; ESMO oral presentation in Dec 2024.
R&D expense $7.2M, G&A $3.1M; $1.5M grant and $20M convertible notes closed in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.